Director Eli Lilly and Company Indianapolis, Indiana
The fourth presentation can tie in-vivo predictive tools data with pre-clinical and clinical data to understand in vivo prediction and help reduce the pre-clinical and clinical study to diminish cost and support accelerating the timeline.
Learning Objectives:
Define Physiologically Based Pharmacokinetic Model (PBBM)
Understand how PBBMs connect in-vitro to in-vivo performance
Understand how PBBMs can be used to assess absorption related risks
